X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma: Its all ‘custom’ made! - Views on News from Equitymaster
StockSelect
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pharma: Its all ‘custom’ made!
Nov 28, 2005

With the introduction of the product patent regime in India, the country is fast becoming an attractive hub for contract manufacturing and contract research. In this article, we take a look at why this business model is gaining importance in India and the potential of the same. Problems at the global level

  1. Escalating R&D costs: The costs involved in developing a drug right from discovery to launch has surged to a massive US$ 800 m to US$ 1 bn. This can be attributed to the fact that the US FDA has become more stringent in the approval of potential drug candidates, requiring companies to provide more data with regards to the safety and efficacy of potential drugs. It must be noted that the global pharma industry has been under fire in recent times owing to risks involved after the launch of drugs. Cases to be noted in particular are the withdrawal of Merck’s anti-arthritic drug ‘Vioxx’ due to the potential risk of heart attacks on use of the drug as well as various anti-depressant drugs of global companies on account of reports connecting the use of these drugs to an increase in the rate of suicides. A combination of these factors has led to an increase in the time taken to develop drugs resulting in fewer launches and mounting research costs.

  2. Mounting Government pressure: In the US and Europe, the aged population as a percentage of total population is on the rise and is expected to rise further by 2025 resulting in a strain in the healthcare budgets. To give a perspective, the ageing population of Europe (as a percentage of regional population) is expected to rise from the current 20% to around 26% by 2025. Similarly that of the US is expected to rise from the current 16% to around 25% by 2025 (Source: Ranbaxy presentation). As a result, governments are under pressure to reduce the healthcare costs.

  3. Patent expiry of drugs: An innovator company stands to lose significant revenues when its product’s patent expires and generic companies enter the market with drugs at a cheaper cost. As a result, with the inevitable rise in R&D costs on one hand and pressure to reduce costs on the other hand, the one viable option left for these innovator companies is to cut down significantly on manufacturing costs.

To Read the Full Story, Subscribe or Sign In


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Feb 23, 2018 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS